Navidea sells shares to support continuing operations

04/24/2013 | Wall Street Journal, The

Navidea Biopharmaceuticals said it has sold shares to JPMorgan Chase & Co.'s asset management unit along with another investor. The company anticipates raising $5.1 million from the move. "We are pleased to be able to capitalize on this opportunity to strengthen our institutional ownership base as we work toward the launch of our first commercial radiopharmaceutical agent, Lymphoseek," said Navidea President and CEO Mark Pykett.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ